Bellecapital International Ltd. Lowers Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Share on StockTwits

Bellecapital International Ltd. lowered its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 7.8% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 1,000 shares of the medical instruments supplier’s stock after selling 85 shares during the period. Bellecapital International Ltd.’s holdings in Becton, Dickinson and were worth $233,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. Mitchell Mcleod Pugh & Williams Inc. lifted its position in Becton, Dickinson and by 1.1% during the second quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 3,815 shares of the medical instruments supplier’s stock valued at $913,000 after buying an additional 40 shares during the period. Capital Bank & Trust Co raised its position in shares of Becton, Dickinson and by 21.2% in the 1st quarter. Capital Bank & Trust Co now owns 246 shares of the medical instruments supplier’s stock worth $57,000 after purchasing an additional 43 shares during the last quarter. Balentine LLC raised its position in shares of Becton, Dickinson and by 45.3% in the 2nd quarter. Balentine LLC now owns 138 shares of the medical instruments supplier’s stock worth $33,000 after purchasing an additional 43 shares during the last quarter. Douglas Lane & Associates LLC raised its position in shares of Becton, Dickinson and by 2.0% in the 2nd quarter. Douglas Lane & Associates LLC now owns 2,443 shares of the medical instruments supplier’s stock worth $585,000 after purchasing an additional 47 shares during the last quarter. Finally, Global Retirement Partners LLC raised its position in shares of Becton, Dickinson and by 21.8% in the 2nd quarter. Global Retirement Partners LLC now owns 274 shares of the medical instruments supplier’s stock worth $66,000 after purchasing an additional 49 shares during the last quarter. 84.18% of the stock is owned by institutional investors and hedge funds.

Several equities analysts have recently issued reports on BDX shares. Barclays raised Becton, Dickinson and from an “equal weight” rating to an “overweight” rating and set a $300.00 price target for the company in a research report on Thursday, July 9th. William Blair reaffirmed an “outperform” rating on shares of Becton, Dickinson and in a research report on Thursday, July 2nd. Morgan Stanley lowered their price target on Becton, Dickinson and from $285.00 to $270.00 and set an “equal weight” rating for the company in a research report on Thursday, August 27th. UBS Group lifted their price target on Becton, Dickinson and from $265.00 to $280.00 and gave the stock a “neutral” rating in a research report on Monday, August 10th. Finally, SVB Leerink lifted their price target on Becton, Dickinson and from $262.00 to $277.00 and gave the stock a “market perform” rating in a research report on Wednesday, July 15th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $278.47.

Shares of Becton, Dickinson and stock traded up $1.98 during trading hours on Friday, reaching $236.99. 1,055,055 shares of the stock traded hands, compared to its average volume of 1,931,858. The company has a 50 day moving average price of $233.68 and a 200 day moving average price of $247.53. The firm has a market capitalization of $68.70 billion, a price-to-earnings ratio of 85.25, a P/E/G ratio of 2.36 and a beta of 0.84. Becton, Dickinson and Company has a one year low of $197.75 and a one year high of $286.72. The company has a quick ratio of 0.97, a current ratio of 1.45 and a debt-to-equity ratio of 0.71.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $2.20 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.04 by $0.16. The business had revenue of $3.86 billion during the quarter, compared to the consensus estimate of $3.96 billion. Becton, Dickinson and had a return on equity of 14.19% and a net margin of 5.30%. The business’s quarterly revenue was down 11.4% compared to the same quarter last year. During the same period in the previous year, the company posted $3.08 EPS. Sell-side analysts anticipate that Becton, Dickinson and Company will post 9.9 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th were paid a dividend of $0.79 per share. The ex-dividend date of this dividend was Tuesday, September 8th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 1.33%. Becton, Dickinson and’s dividend payout ratio is currently 27.05%.

About Becton, Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Further Reading: Google Finance Portfolio Tips and Tricks

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.